Medicina
Departamento
University of Iowa
Iowa City, Estados UnidosPublicaciones en colaboración con investigadores/as de University of Iowa (23)
2023
-
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results
Nature Medicine, Vol. 29, Núm. 9, pp. 2259-2267
-
Evaluation of Intratumoral Response Heterogeneity in Metastatic Colorectal Cancer and Its Impact on Patient Overall Survival: Findings from 10,551 Patients in the ARCAD Database
Cancers, Vol. 15, Núm. 16
-
Response and Outcomes of Maintenance Avelumab After Platinum-Based Chemotherapy (PBC) in Patients With Advanced Urothelial Carcinoma (aUC): “Real World” Experience
Clinical Genitourinary Cancer, Vol. 21, Núm. 5, pp. 584-593
2022
-
Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma
Clinical Genitourinary Cancer, Vol. 20, Núm. 5, pp. e440-e452
-
Association of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancer
BJU International, Vol. 130, Núm. 5, pp. 592-603
-
Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma
Clinical Genitourinary Cancer, Vol. 20, Núm. 6, pp. 558-567
-
Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma
Blood Advances, Vol. 6, Núm. 22, pp. 5835-5843
-
ISARIC-COVID-19 dataset: A Prospective, Standardized, Global Dataset of Patients Hospitalized with COVID-19
Scientific Data, Vol. 9, Núm. 1
-
Mild-to-Moderate Kidney Dysfunction and Cardiovascular Disease: Observational and Mendelian Randomization Analyses
Circulation, Vol. 146, Núm. 20, pp. 1507-1517
-
Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin
Clinical Genitourinary Cancer, Vol. 20, Núm. 2, pp. 165-175
2021
-
A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors
European urology oncology, Vol. 4, Núm. 3, pp. 464-472
-
Anticoagulant selection in relation to the SAMe-TT2R2 score in patients with atrial fibrillation: The GLORIA-AF registry
Hellenic Journal of Cardiology, Vol. 62, Núm. 2, pp. 152-157
-
Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes
BJU International, Vol. 128, Núm. 2, pp. 196-205
2020
-
KDIGO Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation
Transplantation, Vol. 104, Núm. 4S1 Suppl 1, pp. S11-S103
-
Summary of the Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation
Transplantation, Vol. 104, Núm. 4, pp. 708-714
2019
-
Equalization of four cardiovascular risk algorithms after systematic recalibration: Individual-participant meta-analysis of 86 prospective studies
European Heart Journal, Vol. 40, Núm. 7, pp. 621-631
2018
-
Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies
The Lancet, Vol. 391, Núm. 10129, pp. 1513-1523
2016
-
Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database
The Lancet Oncology, Vol. 17, Núm. 12, pp. 1709-1719
2014
-
Effect of evolocumab or ezetimibe added to moderate- Or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: The LAPLACE-2 randomized clinical trial
JAMA, Vol. 311, Núm. 18, pp. 1870-1882
-
Glycated hemoglobin measurement and prediction of cardiovascular disease
JAMA - Journal of the American Medical Association, Vol. 311, Núm. 12, pp. 1225-1233